$Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates$

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

<p>Merestinib and LY2874455 inhibit MET-activated signal transduction. A, AML cell lines treated with merestinib and LY2874455 in vitro for 1 hour exhibited decreased levels of pSTAT3 and pSTAT5 by phospho-flow cytometry. Standard errors are shown for KG1a (n=3) and HEL (n=2) cell lines. Repre...

Full description

Saved in:

Bibliographic Details
Main Author:	Evan C. Chen (15054014) (author)
Other Authors:	Helen Gandler (15054017) (author), Isidora Tošić (15054020) (author), Geoffrey G. Fell (15054023) (author), Ashlee Fiore (15054026) (author), Olga Pozdnyakova (15054029) (author), Daniel J. DeAngelo (15031959) (author), Ilene Galinsky (15054032) (author), Marlise R. Luskin (15054035) (author), Martha Wadleigh (15054038) (author), Eric S. Winer (15054041) (author), Rebecca Leonard (15054044) (author), Kelsey O'Day (15054047) (author), Adrienne de Jonge (15054050) (author), Donna Neuberg (15038318) (author), A. Thomas Look (14951403) (author), Richard M. Stone (15054053) (author), David A. Frank (14961075) (author), Jacqueline S. Garcia (15043140) (author)
Published:	2025
Subjects:	Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Protein kinase & phosphatase drug targets Hematological Cancers Leukemias Pharmacology Pharmacokinetics and pharmacodynamics Precision Medicine Small Molecule Agents Kinase inhibitors Translational Research
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

Similar Items